RSS | Login | Register

PEPCID

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare PEPCID to:

Generic Name for PEPCID

Famotidine 20mg, 40mg; tabs.

Legal Classification:

Pharmacological Class for PEPCID

H₂ blocker.

Manufacturer of PEPCID

Merck & Co., Inc.

Indications for PEPCID

Active duodenal ulcer. Maintenance of healed duodenal ulcer. Active benign gastric ulcer. Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). Gastroesophageal reflux disease (GERD). Esophagitis due to GERD.

Adult dose for PEPCID

Duodenal ulcer: 40mg once daily at bedtime or 20mg twice daily for 4–8 wks. Maintenance: 20mg once daily at bedtime. Benign gastric ulcer: 40mg once daily at bedtime for up to 8 wks. Hypersecretory conditions: Initially 20mg every 6 hrs; individualize. GERD symptoms: 20mg twice daily for up to 6 wks. Esophagitis: 20–40mg twice daily for up to 12 wks (see literature).

Children's dosing for PEPCID

Individualize; adjust based on response. <1yr: not recommended. 1–16yrs: Peptic ulcer: Initially 0.5mg/kg per day at bedtime or in 2 divided doses; max 40mg/day. GERD: Initially 1mg/kg per day divided in 2 doses; max 40mg twice daily.

Also:

PEPCID INJECTION

PEPCID INJECTION PREMIXED

PEPCID SUSPENSION

Warnings/Precautions for PEPCID

Moderate to severe renal insufficiency (CrCl <50mL/min): reduce dose or prolong dosing interval. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for PEPCID

May give antacids concomitantly.

Adverse Reactions for PEPCID

Headache, dizziness, constipation, diarrhea, somnolence, seizures, palpitations, depression, inj site reactions.

How is PEPCID supplied?

Tabs—30, 90, 100, 1000
Susp—50mL
Inj single-dose vials (2mL)—10
Multidose vials (4mL)—1
Multidose vials (20mL)—1, 10
Premixed (50mL)—1

Related Disease:

Duodenal ulcers {DU}

GERD {GERD}

Hypersecretory conditions~Zollinger-Ellison syndrome

Ulcers, duodenal

Ulcers, gastric

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.